Secant Medical Announces Company Name Change

Affirms Commitment to Enabling Technologies for the Medical Device Industry

Secant Medical Announces Company Name Change

<0> Secant MedicalJoannie Anthony, 215-257-8680 x1199 </0>

Secant Medical, LLC, which specializes in the custom design, development and manufacturing of implantable biomedical textiles, and its parent company Prodesco Inc., will merge under one unified company name. Effective September 1, 2012, both companies will become Secant Medical, Inc., to support its continued business growth in the medical device industry.

“Our company will maintain the same values and collaborative engineering approach while further expanding our business to better serve the needs our clients,” said Erik Nadeau, president. “The name change signifies our commitment to being an innovator in enabling technology platforms and our focus on adapting to the ever changing needs of the medical device industry.”

Secant Medical, LLC was formed as a business unit of Prodesco in 2002 and has quickly become the major growth driver for the business. The change to Secant Medical, Inc. positions the company to grow in a challenging and dynamic market with a clear focus on improving the health of patients worldwide. Prodesco will remain a brand of Secant Medical, Inc.

Secant Medical specializes in custom-developed biomedical textile structures for medical devices, helping clients meet challenges to bring device solutions to market with sustained value for the future. Using constantly evolving advanced polymeric, metallic and resorbable biomaterials, the company develops advanced implantable textile structure technologies that enable client innovation in orthopedic, cardiovascular, tissue-engineered, neurovascular and general surgery devices. Secant Medical is a business unit of Fenner PLC, a worldwide leader in reinforced polymer engineering headquartered in Yorkshire, England. For more information, contact Joannie Anthony at 215-257-8680 x1199 or , or visit .

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.